Specific treatments with regard to each peripheral musculoskeletal manifestation*
| Root joint involvement N=1503 | Peripheral joint disease N=2541 | Enthesitis N=1984 | Dactylitis N=685 | |
| NSAIDs | 1191 (79.2%) | 2317 (91.2%) | 1318 (66.4%) | 489 (71.4%) |
| Prescribed for >1 peripheral manifestation | 925/1191 (77.7%) | 1449/2317 (62.5%) | 1052/1318 (79.8%) | 467/489 (95.5%) |
| Systemic glucocorticoids | NC | 1100 (43.3%) | 289 (14.6%) | NC |
| Prescribed for >1 peripheral manifestation | 235/1100 (21.4%) | 235/1984 (11.8%) | ||
| csDMARDs | 686 (45.6%) | 1962 (77.2%) | 665 (33.5%) | 377 (55.0%) |
| Prescribed for >1 peripheral manifestation | 561/686 (81.8%) | 976/1962 (49.7%) | 561/665 (84.4%) | 354/377 (93.9%) |
| bDMARDs | 455 (30.3%) | 1066 (42.0%) | 443 (22.3%) | 177 (25.8%) |
| Prescribed for >1 peripheral manifestation | 302/455 (66.4%) | 521/1066 (48.9%) | 344/443 (77.7%) | 164/177 (92.7%) |
| Local injections glucocorticoids | 215 (14.3%) | 778 (30.6%) | 161 (8.1%) | 89 (13.0%) |
| Prescribed for >1 peripheral manifestation | 101/215 (47.0%) | 207/778 (26.6%) | 83/161 (51.6%) | 61/89 (68.5%) |
| Total articular replacement | 136 (9.0%) | 20 (0.8%) | NC | NC |
| Prescribed for >1 peripheral manifestation | 4/136 (2.9%) | 4/20 (20.0%) | ||
| Any treatment | 1251 (83.2%) | 2457 (96.7%) | 1364 (68.8%) | 536 (78.2%) |
*Data concerning treatment for midfoot arthritis were not collected.
bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; NC, not collected; NSAIDs, non-steroidal anti-inflammatory drugs.